All In Biotech

Drug Trial Radar · NCT07399704

A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease

Open-label Study to Evaluate the Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease, With or Without Previous Administration of Miglustat

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

21

Planned (sponsor's estimate)

Start

Feb 4, 2026

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Azafaros B.V.Industry
Sponsor type
Industry
First posted
Feb 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label study aims to gather long-term safety, tolerability, PK, biomarker, and clinical efficacy data relating to daily administration of Nizubaglustat in participants previously enrolled in the Phase 2 RAINBOW study (Cohort 1). In addition, the study aims to assess safety, clinical, and biochemical impact of transitioning NPC disease patients to Nizubaglustat after prior treatment with stable, full-dose Miglustat (Cohort 2).

Conditions

  • GM2 Gangliosidosis
  • Niemann-Pick Type C Disease

Interventions

  • AZ-3102Drug

    Daily oral intake of AZ-3102 dispersible tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in treatment-emergent adverse events (TEAEs)Time frame: Through study completion, an average of 4 years
  2. Change from baseline in electrocardiogram (ECG)Time frame: Through study completion, an average of 4 years
  3. Change from baseline in seizuresTime frame: Through study completion, an average of 4 years
  4. Change from baseline in seizuresTime frame: Through study completion, an average of 4 years
  5. Maximum observed plasma concentration (Cmax)Time frame: Baseline , Month 1 (Cohort 2 only) and Month 6
  6. Time to Cmax (Tmax)Time frame: Baseline, Month 1 (Cohort 2 only) and Month 6
  7. Concentration at trough (Ctrough)Time frame: Baseline, Month 1 (Cohort 2 only) and Month 6
  8. Area under the plasma concentration-time curve from the time of dosing (zero) to 24 hours post-doseTime frame: Baseline, Month 1 (Cohort 2 only) and Month 6

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira

    Rio de Janeiro, Brazil

  • Associação Hospitalar de Prot à Infância Dr. Raul Carneiro

    Água Verde, Curitiba, Brazil

  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.